MedTrace Logo

Insight Into the UAE Experience With Monoclonal Antibodies (Sotrovimab )

NCT05144178 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 3500

Last updated 2022-01-03

No results posted yet for this study

Summary

Sotrovimab is a newly developed monoclonal antibody for the treatment of mild and moderate COVID-19 patient, who are at high risk for progression to severe COVID-19, including hospitalization or death. This includes, for example, individuals who are 65 years of age and older or individuals who have certain medical conditions.

The safety and effectiveness of this investigational therapy continues to be evaluated for treatment of COVID-19. Sotrovimab is not authorized for patients who are hospitalized due to COVID-19 or require oxygen therapy due to COVID-19.

As the clinical trial results are too preliminary for the drug to enter routine use in UAE the drug approved only for emergency use, until further evidence shows Sotrovimab is effective, so we thought about this study as a tool to assess the success of Emirats Health service (EHS) strategy for fighting against COVID-19 outside the hospital setting.

Conditions

  • COVID-19 Respiratory Infection

Sponsors & Collaborators

  • Emirates Health Services (EHS)

    lead OTHER_GOV

Principal Investigators

  • sumaya abdalateef · Emirats Health Service (EHS)

Eligibility

Min Age
13 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-11-14
Primary Completion
2022-01-30
Completion
2022-02-09

Countries

  • United Arab Emirates

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05144178 on ClinicalTrials.gov